Pfizer to acquire New Haven migraine drugmaker Biohaven for $11.6 billion
The announcement comes six months after Pfizer began a collaboration to commercialize Biohaven's migraine drug Nurtec outside of the United States. |!| New Haven
More from Greater New Haven
Post Eagles
Men's Soccer back in win column as Padroni's goal bests Jefferson, 1-0
Greater New Haven
•
6m ago
New Haven Register
Yale football falls to Rhode Island despite Hugo Djeumeni Kemeni's 243-yard rushing game
Greater New Haven
•
53m ago
Southern Connecticut State Owls
SCSU Women's Soccer Falls To Saint Anselm
Greater New Haven
•
1h ago
New Haven Chargers
New Haven's Defense Stifles Robert Morris, Powers Blue & Gold to 26-15 Victory
Greater New Haven
•
2h ago
